Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Puma Biotechnology (NASDAQ:PBYI) is the #1 top biotech stock out of 604 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: C, Momentum: A, Sentiment: B, Safety: C, Financials: A, and AI: B.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 48, which is 24 points higher than the biotech industry average of 24.

PBYI passed 15 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock return 120.18% over the past year, overperforming other biotech stocks by 141 percentage points.

Puma Biotechnology has an average 1 year price target of $6.00, a downside of -38.9% from Puma Biotechnology's current stock price of $9.82.

Puma Biotechnology stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Beone Medicines (NASDAQ:ONC) is the #2 top biotech stock out of 604 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Beone Medicines (NASDAQ:ONC) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: B.

Beone Medicines (NASDAQ:ONC) has a Due Diligence Score of 28, which is 4 points higher than the biotech industry average of 24.

ONC passed 9 out of 33 due diligence checks and has average fundamentals. Beone Medicines has seen its stock return 8.96% over the past year, overperforming other biotech stocks by 30 percentage points.

Beone Medicines has an average 1 year price target of $412.00, an upside of 11.93% from Beone Medicines's current stock price of $368.08.

Beone Medicines stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Beone Medicines, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the #3 top biotech stock out of 604 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Harmony Biosciences Holdings (NASDAQ:HRMY) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: B.

Harmony Biosciences Holdings (NASDAQ:HRMY) has a Due Diligence Score of 53, which is 29 points higher than the biotech industry average of 24.

HRMY passed 17 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock return 28.1% over the past year, overperforming other biotech stocks by 49 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $47.67, an upside of 14.78% from Harmony Biosciences Holdings's current stock price of $41.53.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 0% have issued a Strong Buy rating, 66.67% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 7 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 5.26%, which is 3 percentage points higher than the biotech industry average of 1.8%.

Oramed Pharmaceuticals's dividend payout ratio of 5.9% indicates that its high dividend yield is sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 4.7%, which is 3 percentage points higher than the biotech industry average of 1.8%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 46.1% indicates that its high dividend yield is sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.58%, which is the same as the biotech industry average of 1.8%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 48.4% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were up 1.3% in the last day, and up 1.83% over the last week. Jaguar Health was the among the top gainers in the biotechnology industry, gaining 1,190.64% yesterday.

Jaguar Health shares are trading higher after the company announced that the FDA granted the Napo Pharmaceutical's request for a fee waiver associated with the Prescription Drug User Fee Act for Mytesi.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 28.1% in the past year. It has overperformed other stocks in the biotech industry by 49 percentage points.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has gained 84.78% in the past year. It has overperformed other stocks in the biotech industry by 106 percentage points.

Exelixis (NASDAQ:EXEL) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Exelixis has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Exelixis's stock has gained 46.92% in the past year. It has overperformed other stocks in the biotech industry by 68 percentage points.

65.67% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 58.79% over the next year.

3.06% of biotech stocks have a Zen Rating of A (Strong Buy), 3.71% of biotech stocks are rated B (Buy), 44.1% are rated C (Hold), 38.21% are rated D (Sell), and 10.92% are rated F (Strong Sell).